Trazodone Label Update Sharpens Safety Boundaries Around Depression Treatment
DailyMed’s updated prescribing information for trazodone hydrochloride places safety front and center. The label keeps the drug’s approved role narrow: treatment of major depressive disorder in adults, with a boxed warning for suicidal thoughts and behaviors in pediatric and young adult patients. It also reinforces that trazodone is not approved for pediatric use, a point that matters clinically because antidepressant exposure in younger patients demands closer monitoring for behavioral change, worsening depression, and emergent self-harm risk.
The label’s structure reflects a familiar tension in antidepressant care. Trazodone offers a serotonergic mechanism that can be useful in depression, but the same pharmacology creates a cluster of predictable hazards: serotonin toxicity, cardiac conduction effects, sedation, blood pressure lability, and interaction-driven exposure changes. In practice, the drug is less a simple antidepressant than a medication whose benefit depends on careful dosing, timing with food, and thoughtful review of the patient’s other therapies.
Dosing Strategy Balances Efficacy With Tolerability
The recommended starting dose is 150 mg per day in divided doses, with increases of 50 mg per day every three to four days as needed. The maximum dose is 400 mg per day in divided doses. Tablets are available as scored 50 mg, 100 mg, 150 mg, and 300 mg strengths, which gives prescribers some flexibility in titration and dose splitting. The label instructs that tablets should be taken shortly after a meal or light snack, swallowed whole or broken along the score line, and not chewed or crushed.
Those instructions are not cosmetic details. Food can help with tolerability, especially when sedation or gastrointestinal effects emerge early in treatment, and the recommendation to avoid crushing preserves predictable oral delivery. When discontinuing therapy, gradual dose reduction is recommended, a practical safeguard against withdrawal symptoms and abrupt clinical destabilization.
A slow taper is not optional housekeeping; it is part of the treatment plan.
Serotonin Toxicity and Cardiac Risk Sit at the Center of Prescribing Decisions
One of the clearest warnings involves serotonin syndrome. The risk rises when trazodone is combined with other serotonergic agents such as SSRIs, SNRIs, and triptans, but the label also notes that it can occur even when trazodone is taken alone. If serotonin syndrome develops, trazodone should be discontinued and supportive treatment initiated. Clinically, that warning matters because many patients with depression, migraine, chronic pain, or anxiety already take overlapping serotonergic drugs, and the interaction burden can accumulate quietly before symptoms become obvious.
The label also warns that trazodone can increase the QT interval. Avoidance is advised in patients with risk factors for prolonged QT interval and in those taking other drugs that also prolong QT. This is a meaningful caution in real-world psychiatry and primary care, where patients often have occult electrolyte disturbances, structural heart disease, or polypharmacy that is not obvious at first glance. Even modest QT effects can become relevant when layered onto existing cardiac vulnerability.
Orthostasis, Sedation, and Falls Remain Bedside Problems
Trazodone carries a warning for orthostatic hypotension and syncope. The label directs clinicians to warn patients about the symptoms of hypotension, which is especially relevant when treatment begins or doses are increased. Drowsiness, fatigue, and syncope appear among the most common adverse reactions, along with edema, blurred vision, diarrhea, nasal congestion, and weight loss. Cognitive and motor impairment is also specifically listed, with advice to use caution when operating machinery.
These effects converge in a way that can be clinically consequential. A patient who is sedated, lightheaded, and intermittently hypotensive is at higher risk for injury, impaired driving, and medication nonadherence. The label’s warning is especially important in older adults or in anyone already taking antihypertensives, other sedatives, or medications that affect balance and alertness.
Bleeding, Mania, and Priapism Extend the Safety Checklist
The prescribing information also addresses increased bleeding risk. Concomitant use with aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase that risk. The mechanism is consistent with serotonergic effects on platelet function, which can magnify baseline bleeding risk in patients with cardiovascular disease or chronic pain who already rely on antiplatelet or anticoagulant therapy.
Another warning concerns activation of mania or hypomania. Screening for bipolar disorder before treatment and monitoring during therapy are recommended. In a depressive presentation, this is not a theoretical concern; antidepressant treatment can unmask bipolar illness or intensify mood instability when the underlying diagnosis has not been recognized.
Priapism deserves special attention because it is uncommon but urgent. Cases of painful and prolonged penile erections have been reported, and immediate medical attention is advised if symptoms appear. For prescribers, this warning is a reminder that a sexual adverse event can become a urologic emergency when the erection is prolonged.
Contraindications and Drug Interactions Narrow the Safe Operating Window
Concomitant use of monoamine oxidase inhibitors is contraindicated, as is use within 14 days of stopping an MAOI. The interaction profile extends further through CYP3A4. Strong CYP3A4 inhibitors may require trazodone dose reduction based on tolerability, while CYP3A4 inducers may necessitate a dosage increase. The label also calls for monitoring when trazodone is used with digoxin or phenytoin, and it warns that warfarin levels may be affected in either direction, requiring prothrombin time surveillance.
Trazodone may enhance the effects of alcohol, barbiturates, and other CNS depressants. In practical terms, that means the medication can amplify sedation and psychomotor slowing beyond what either agent produces alone. The prescribing information also warns against use in patients with untreated anatomically narrow angles because antidepressants, including trazodone, can precipitate angle-closure glaucoma.
Use in Specific Populations Leaves Little Room for Complacency
The boxed warning, the pediatric restriction, and the need for careful monitoring across age groups place trazodone in a high-attention category even though it is an established antidepressant. The label’s broad message is straightforward: the drug can be effective for depression, but its use should be paired with deliberate screening, medication reconciliation, and follow-up for neurologic, cardiovascular, and behavioral adverse effects.
Hyponatremia is also listed among the warnings and precautions, adding another layer of monitoring in vulnerable patients, particularly those with multiple comorbidities or concomitant medications that can affect sodium balance. Pregnancy and lactation sections are included in the full label, but the core clinical message remains centered on adult prescribing discipline, dose titration, and adverse effect surveillance.
This update does not change trazodone’s place in therapy, but it does make the boundaries clearer: avoid MAOIs, watch for serotonin toxicity, respect QT risk, monitor for hypotension and sedation, and do not treat the warning labels as peripheral text. In a drug with broad serotonergic activity, the safety details are inseparable from the prescription itself.